Piramal Enterprises Limited
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 3, 2027The maintenance fee for Compounds containing carbon-carbon linker as GPR120 agonists (US 11,773,077) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Jun 12, 2027The maintenance fee for Pharmaceutical combination for the treatment of melanoma (US 11,839,591) comes due Jun 12, 2027. Unpaid by Dec 13, 2027, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Pharmaceutical combination for the treatment of cancer (US 10,555,931) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Pharmaceutical combination for the treatment of cancer (US 11,925,618) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 3 terms have ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,206,756 | Herbal composition for inflammatory disorders In force · USPTO record | In force | USPTO record | |
| US 8,822,526 | Synergistic pharmaceutical combination for the treatment of cancer In force · USPTO record | In force | USPTO record | |
| US 8,563,596 | Enantiomerically pure compounds for the treatment of proliferative disorders In force · USPTO record | In force | USPTO record | |
| US 8,906,953 | Pyrrolidine substitute flavones for the treatment of inflammatory disorders In force · USPTO record | In force | USPTO record | |
| US 8,895,605 | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer In force · USPTO record | In force | USPTO record | |
| US 10,245,251 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck In force · USPTO record | In force | USPTO record | |
| US 10,980,776 | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck In force · USPTO record | In force | USPTO record | |
| US 10,688,079 | Compounds for the Treatment of Cancers Associated with Human Papillomavirus In force · High confidence | In force | High confidence | |
| US 11,160,789 | Compounds for the Treatment of Cancers Associated with Human Papillomavirus In force · High confidence | In force | High confidence | |
| US 12,076,309 | Compounds for the Treatment of Cancers Associated with Human Papillomavirus In force · High confidence | In force | High confidence |
Also on record, not counted in the 22: 10 patents in force now held by others · 45 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 4 abandoned · 33 no status recorded